Expression of Excision Repair Cross-Complementation Group 1 as Predictive Marker for Nasopharyngeal Cancer Treated With Concurrent Chemoradiotherapy

Purpose Cisplatin-based concurrent chemoradiotherapy is the standard treatment of nasopharyngeal cancer. The expression of excision repair cross-complementation group 1 (ERCC1) has been reported to be associated with resistance to platinum-based chemotherapy. We evaluated whether ERCC1 expression co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of radiation oncology, biology, physics biology, physics, 2011-07, Vol.80 (3), p.655-660
Hauptverfasser: Sun, Jong-Mu, M.D, Ahn, Myung-Ju, M.D., Ph.D, Park, Min Jae, M.D, Lee, Hui-Young, M.D, Ahn, Jin Seok, M.D., Ph.D, Lee, Seungkoo, M.D, Kang, Gu, M.D, Han, Joungho, M.D., Ph.D, Son, Young-Ik, M.D., Ph.D, Baek, Chung-Hwan, M.D., Ph.D, Ahn, Yong Chan, M.D., Ph.D, Park, Keunchil, M.D., Ph.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!